Winter Park, FL – According to filings with the U.S. Securities and Exchange Commission, Cytocom is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Handley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cytocom

Cytocom, Inc. is a clinical-stage biopharmaceutical company developing a new class of Immunotherapies targeting cancers, infectious diseases, and autoimmune disorders utilizing a new systems biology approach creating first-in-class or best-in-class therapies. Our therapies may be standalone therapies or may be adjunctive therapies that improve upon the efficacy and safety of standard of care. .

To learn more about Cytocom, visit http://www.cytocom.com/

Contact:
Michael Handley, Chief Executive Officer
888-629-4155
https://www.linkedin.com/in/mike-handley-939b844/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved